'CIIE Babies' powered by fast-track approval

Since the first China International Import Expo (CIIE) in 2018, many innovative drugs and medical devices in the medical and pharmaceuticals field have quickly transformed from exhibits to commodities through the CIIE and been put into use in China. These innovative drugs and devices are affectionately referred to as "CIIE Babies" by exhibitors. The fast - track approval has played a crucial role in this process, which is demonstrated by the following cases:Edwards Lifesciences: In 2020, the INSPIRIS RESILIA aortic valve by Edwards Lifesciences made its debut at the CIIE and obtained market approval in China in less than two months. Another product, the SAPIEN3 transcatheter aortic valve system, completed its first commercial implantation in Shanghai within a month after its debut at the CIIE and was subsequently included in the medical insurance systems of Henan and Shanghai.Novo Nordisk: In 2024, Novo Nordisk unveiled the world's first weekly insulin formulation at the CIIE and achieved commercial launch and medical insurance approval simultaneously in China by the end of the month. This product achieved a triple leap from laboratory research to exhibits and then to marketable products within just one year.Boehringer Ingelheim: At the third CIIE in 2020, Boehringer Ingelheim introduced the world's first targeted biologic agent for generalized pustular psoriasis (GPP) - Spesolimab. The drug achieved synchronized research, registration, and approval globally, ahead of the US, EU, and Japan in preventing GPP. Within just a few years, the pharmaceutical solution progressed from CIIE debut to global first launch.The "CIIE Acceleration" not only reflects the rapid translation of innovative outcomes but also shortens the time for patients to access new drugs and medical devices, bringing more treatment options and hopes to patients.